DESTINY, 2024 Flashcards
1
Q
Study question for Destiny trial?
A
T-DXd HERT2 directed ADC approved in HER2+ breast and GI and HER2mut non SCLC; there are other HER2 solid tumors
2
Q
Study design for DESTINY?
A
Ph II, T-DXd (5.4 q 3 wk)
Safety, DOR, PFS and OS
3
Q
Make up of T-DXd
A
-Humanized IgG1 anti-HER2 mAb
-Tetrapeptide-based cleavable linker
-Topoisomerase 1 inh payload
4
Q
Inclusion criteria for DESTINY trial?
A
T-DXd -
for HER2 IHC 3+/2+ by local or central testing for locally adv or mets disease s/p 1+ treatment or no alternatives; needed measurable disease
5
Q
Results of the DESTINY trial?
A
n=267; ORR 37% for all (~60% in HER2+); median DOR 11.3mo (22mo); PFS 7 mo (12mo); median OS 13.4mo (21 mo)
6
Q
Adverse effects of DESTINY trial?
A
10% with ILD; 40% G3 AEs
